Cell binding agent conjugates of analogues and derivatives of CC-1065

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5475092
SERIAL NO

08210742

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel cytotoxic agents comprising a cell binding agent chemically linked to one or more analogue or derivative of CC-1065 are described. The therapeutic use of the cytotoxic agents is also described. These cytotoxic agents have therapeutic use because they deliver the cytotoxic drugs to a specific cell population in a targeted fashion.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IMMUNOGEN, INC.WALTHAM, MA121

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Blattler, Walter A Brookline, MA 33 1406
Chari, Ravi V J Newton, MA 79 1627
Goldmakher, Viktor S Newton, MA 22 439

Cited Art Landscape

Patent Info (Count) # Cites Year
 
BRISTOL-MYERS SQUIBB COMPANY (1)
* 4301248 Fermentation process for making rachelmycin 5 1980
 
Checkfree Services Corporation (1)
7809639 System and method to provide interoperable service across multiple clients 6 2002
 
NeoRx Corporation (1)
* 5106951 Antibody conjugates 70 1989
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
* 5045451 Methods for screening antibodies for use as immunotoxins 74 1988
 
UPJOHN COMPANY, THE (1)
* 4912227 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds 36 1986
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
LUDWIG INSTITUTE FOR CANCER RESEARCH (4)
9283276 Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof 0 2008
9072798 Specific binding proteins and uses thereof 0 2010
9562102 Specific binding proteins and uses thereof 0 2012
9260524 Specific binding proteins and uses thereof 0 2012
 
Other [Check patent profile for assignment information] (3)
9815784 CC-1065 analogs and their conjugates 0 2014
9822186 Bispecific antibodies that bind to CD38 and CD3 0 2015
9815902 Humanized anti-CXCR5 antibodies, derivatives thereof and their uses 0 2016
 
IMMUNOGEN, INC. (54)
6340701 Cytotoxic agents comprising taxanes and their therapeutic use 67 2000
6372738 Cytotoxic agents comprising taxanes and their therapeutic use 34 2001
6436931 Cytotoxic agents comprising taxanes and their therapeutic use 42 2002
6756397 Prodrugs of CC-1065 analogs 33 2002
* 2003/0199,519 Prodrugs of CC-1065 analogs 7 2002
6706708 Cytotoxic agents comprising taxanes and their therapeutic use 20 2002
7390898 Cytotoxic agents containing novel potent taxanes and their therapeutic use 6 2003
* 2004/0024,049 Cytotoxic agents containing novel potent taxanes and their therapeutic use 12 2003
7008942 Cytotoxic agents comprising taxanes and their therapeutic use 6 2003
7049316 Prodrugs of CC-1065 analogs 13 2003
* 2004/0109,867 Prodrugs of CC-1065 analogs 6 2003
7374762 Drug conjugate composition 16 2004
7495114 Cytotoxic agents containing novel potent taxanes and their therapeutic use 6 2004
7414073 Cytotoxic agents containing novel potent taxanes and their therapeutic use 7 2004
7217819 Cytotoxic agents comprising taxanes and their therapeutic use 6 2005
7388026 Prodrugs of CC-1065 analogs 10 2005
* 2006/0009,462 Prodrugs of CC-1065 analogs 6 2005
7528130 Cytotoxic agents comprising taxanes and their therapeutic use 6 2006
7276499 Cytotoxic agents comprising taxanes and their therapeutic use 6 2006
* 2006/0182,750 Process for preparing stable drug conjugates 20 2006
9114179 Immunoconjugate formulations 0 2006
* 2007/0031,402 Immunoconjugate formulations 62 2006
7811572 Process for preparing purified drug conjugates 10 2006
* 2007/0048,314 Process for preparing purified drug conjugates 16 2006
7514080 Drug conjugate composition 14 2006
7501120 Drug conjugate composition 13 2006
7494649 Drug conjugate composition 13 2006
* 2007/0009,539 Drug conjugate composition 1 2006
7655660 Prodrugs of CC-1065 analogs 12 2007
* 2007/0135,346 Prodrugs of CC-1065 analogs 7 2007
8840898 Immunoconjugates targeting syndecan-1 expressing cells and use thereof 1 2007
* 2007/0183,971 IMMUNOCONJUGATES TARGETING SYNDECAN-1 EXPRESSING CELLS AND USE THEREOF 5 2007
7550609 Cytotoxic agents comprising taxanes and their therapeutic use 6 2007
7476669 Cytotoxic agents comprising taxanes and their therapeutic use 6 2007
7585857 Cytotoxic agents comprising taxanes and their therapeutic use 10 2007
7655661 Prodrugs of CC-1065 analogs 10 2008
* 2008/0260,685 PRODRUGS OF CC-1065 ANALOGS 6 2008
8012978 Prodrugs of CC-A1065 analogs 4 2008
* 2009/0028,821 PRODRUGS OF CC-A1065 ANALOGS 8 2008
8012485 Drug conjugate composition 5 2009
7906545 Prodrugs of CC-1065 analogs 2 2009
* 2009/0281,158 PRODRUGS OF CC-1065 ANALOGS 6 2009
8383122 Process for preparing purified drug conjugates 10 2010
* 2011/0166,319 PROCESS FOR PREPARING PURIFIED DRUG CONJUGATES 12 2010
9238690 Non-antagonistic EGFR-binding molecules and immunoconjugates thereof 0 2011
8790649 EGFR-binding molecules and immunoconjugates thereof 4 2011
8795673 Preparation of maytansinoid antibody conjugates by a one-step process 5 2012
9233171 Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate 0 2012
8933205 Process for preparing purified drug conjugates 4 2013
9125896 EGFR-binding molecules and immunoconjugates thereof 0 2013
9376500 Conjugation methods 1 2013
9428543 Preparation of maytansinoid antibody conjugates by a one-step process 0 2014
9789204 Process for preparing purified drug conjugates 0 2015
9771432 Conjugation methods 0 2016
 
The Scripps Research Institute (2)
* 6262271 ISO-CBI and ISO-CI analogs of CC-1065 and the duocarmycins 19 2000
6486326 iso-CBI and iso-CI analogs of CC-1065 duocarmycins 18 2001
 
IMMUNOGEN, INC. (ONE-HALF INTEREST) (5)
9446146 Methods and agents for improving targeting of CD138 expressing tumor cells 0 2008
9387261 Immunoconjugates targeting CD138 and uses thereof 0 2008
9011864 Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates 0 2008
* 2009/0232,810 IMMUNOCONJUGATES TARGETING CD138 AND USES THEREOF 3 2008
* 2009/0181,038 METHOD OF DECREASING CYTOTOXIC SIDE-EFFECTS AND IMPROVING EFFICACY OF IMMUNOCONJUGATES 5 2008
 
PROLX PHARMACEUTICALS CORP. (2)
6552060 Asymmetric disulfides and methods of using same 8 1998
* 2003/0176,512 Asymmetric disulfides and methods of using same 3 2003
 
RIGEL PHARMACEUTICALS, INC. (1)
* 2005/0215,614 Substituted indoles and their use as hcv inhibitors 17 2005
 
ELUTEX LTD. (2)
* 2006/0013,850 Electropolymerizable monomers and polymeric coatings on implantable devices prepared therefrom 62 2005
* 2009/0123,514 Electropolymerizable Monomers and Polymeric Coatings on Implantable Devices Prepared Therefrom 1 2006
 
E. R. SQUIBB & SONS, L.L.C. (22)
7129261 Cytotoxic agents 55 2002
6989452 Disulfide prodrugs and linkers and stabilizers useful therefor 46 2002
7691962 Chemical linkers and conjugates thereof 38 2005
7517903 Cytotoxic compounds and conjugates 36 2005
* 2006/0024,317 Chemical linkers and conjugates thereof 39 2005
* 2006/0004,081 Cytotoxic compounds and conjugates 15 2005
7498302 Disulfide prodrugs and linkers and stabilizers useful therefor 20 2005
* 2005/0272,798 Disulfide prodrugs and linkers and stabilizers useful therefor 14 2005
7507420 Peptidyl prodrugs and linkers and stabilizers useful therefor 27 2005
* 2006/0013,860 Peptidyl prodrugs and linkers and stabilizers useful therefor 4 2005
7714016 Cytotoxic compounds and conjugates with cleavable substrates 13 2006
8124738 Human monoclonal antibodies to CD70 16 2006
* 2009/0028,872 HUMAN MONOCLONAL ANTIBODIES TO CD70 9 2006
7847105 Methods and compounds for preparing CC-1065 analogs 9 2006
7968586 Cytotoxic compounds and conjugates 9 2006
8461117 Chemical linkers and cleavable substrates and conjugates thereof 1 2007
8664407 Chemical linkers with single amino acids and conjugates thereof 1 2008
* 2010/0113,476 CHEMICAL LINKERS WITH SINGLE AMINO ACIDS AND CONJUGATES THEREOF 23 2008
* RE41252 Peptidyl prodrugs and linkers and stabilizers useful therefor 2 2008
8034959 Methods of treating cancer with an antibody-drug conjugate 13 2009
7977465 Peptidyl prodrugs and linkers and stabilizers useful therefor 8 2009
8399403 Chemical linkers and conjugates thereof 1 2009
 
SANOFI (20)
8460667 EPHA2 receptor antagonist antibodies 2 2007
* 2010/0047,257 ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER 21 2007
8153765 Anti-CD38 antibodies for the treatment of cancer 3 2007
* 2009/0304,710 NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER 14 2007
8647622 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 3 2008
* 2011/0027,266 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2008
8388965 Antibodies that bind IL-4 and/or IL-13 and their uses 21 2008
* 2010/0226,923 ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES 6 2008
8404678 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use 7 2010
8668910 Antibodies that specifically bind to the EphA2 receptor 1 2010
9738728 Antibodies that bind IL-4 and/or IL-13 and their uses 0 2013
9243067 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2013
9228019 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2013
9175087 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2013
8980262 Humanized anti-CXCR5 antibodies, derivatives thereof and their use 0 2013
9732162 Antibodies that bind IL-4 and/or IL-13 and their uses 0 2013
9592289 Stable IgG4 based binding agent formulations 0 2013
9676864 Antibodies that specifically bind to the EphA2 receptor 0 2014
9617345 Anti-CEACAM5 antibodies and uses thereof 0 2015
9809653 Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof 0 2015
 
REDWOOD BIOSCIENCE, INC. (2)
9238878 Aldehyde-tagged protein-based drug carriers and methods of use 0 2010
9540438 Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof 0 2012
 
XENCOR, INC. (7)
9493578 Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens 0 2010
8637641 Antibodies with modified isoelectric points 11 2011
9701759 Heterodimeric proteins 0 2014
9738722 Rapid clearance of antigen complexes using novel antibodies 0 2014
9605061 Antibodies with modified isoelectric points 0 2014
9605084 Heterodimeric proteins 0 2014
9650446 Heterodimeric proteins 0 2014
 
SIAMAB THERAPEUTICS, INC. (2)
9273142 Glycan-interacting compounds 0 2013
9416194 Glycan-interacting compounds 0 2016
 
SYNTHON BIOPHARMACEUTICALS B.V. (1)
9421278 Duocarmycin ADCS showing improved in vivo antitumor activity 2 2015
 
IMMUNOGENT INC. (1)
* 2006/0122,259 Cytotoxic agents comprising taxanes and their therapeutic use 0 2006
 
BIOTEST AG (2)
9221914 Agents targeting CD138 and uses thereof 0 2008
* 2009/0175,863 AGENTS TARGETING CD138 AND USES THEREOF 5 2008
 
JCRT Radiation Oncology Support Services, Inc. (2)
6368598 Drug complex for treatment of metastatic prostate cancer 24 1998
* 2005/0233,948 Drug complex for treatment of metastatic prostate cancer 28 2005
 
YALE UNIVERSITY (1)
9427480 Duocarmycin ADCs for use in treatment of endometrial cancer 2 2015
 
ALCHEMIA ONCOLOGY PTY LIMITED (10)
8287894 Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease 3 2005
* 2005/0267,069 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease 7 2005
9066919 Hyaluronan as a chemo-sensitizer in the treatment of cancer 0 2005
8388993 Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer 3 2006
* 2006/0263,395 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease 5 2006
8937052 Therapeutic protocols using hyaluronan 0 2006
* 2009/0054,537 THERAPEUTIC PROTOCOLS USING HYALURONAN 5 2006
8623354 Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment 4 2006
* 2009/0306,012 THERAPEUTIC PROTOCOLS 6 2009
8741970 Composition and method for the enhancement of the efficacy of drugs 2 2011
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2)
9023356 Treatment method using EGFR antibodies and SRC inhibitors and related formulations 0 2008
9433686 Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function 0 2012
 
ARCHEMIX LLC (1)
8853376 Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics 0 2011
 
MEMORIAL SLOAN-KETTERING CANCER CENTER (2)
9169328 Antibodies to MUC16 and methods of use thereof 1 2011
9790283 Antibodies to MUC16 and methods of use thereof 0 2015
 
THE GENERAL HOSPITAL CORPORATION (1)
8900549 Compositions and methods for delivering a substance to a biological target 0 2009
 
MEDAREX, L.L.C. (3)
7087600 Peptidyl prodrugs and linkers and stabilizers useful therefor 42 2002
* 2003/0064,984 Peptidyl prodrugs and linkers and stabilizers useful therefor 4 2002
* 2010/0150,950 HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF 11 2007
 
BAYLOR COLLEGE OF MEDICINE (1)
* 5780446 Formulations of vesicant drugs and methods of use thereof 20 1996
 
ARCHEMIX CORP. (1)
* 2004/0022,727 Aptamer-toxin molecules and methods for using same 31 2003
 
SYNTARGA BV (2)
8889868 CC-1065 analogs and their conjugates 3 2009
9629924 Conjugates of CC-1065 analogs and bifunctional linkers 0 2011
 
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (1)
9133239 Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration 0 2011
 
DANA-FARBER CANCER INSTITUTE, INC. (1)
9090693 Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease 0 2008
 
COMPUGEN LTD. (4)
* 2007/0082,337 Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby 9 2005
* 2006/0068,405 Methods and systems for annotating biomolecular sequences 11 2005
7745391 Human thrombospondin polypeptide 137 2006
* 2007/0083,334 Methods and systems for annotating biomolecular sequences 93 2006
 
SCHOLAR ROCK, INC. (3)
9758576 Compositions and methods for growth factor modulation 0 2015
9573995 Compositions and methods for growth factor modulation 0 2015
9399676 Compositions and methods for growth factor modulation 1 2015
 
AMGEN INC. (1)
9464139 GITR antigen binding proteins and methods of use thereof 0 2014
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (1)
* 2003/0099,684 Electropolymerizable monomers and polymeric coatings on implantable devices 30 2002
* Cited By Examiner